Updated Jul 16, 2026
Duker Jay S. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $20K.
Jay S. Duker is the President and CEO of EyePoint Pharmaceuticals, Inc., a company focused on developing innovative therapeutics for retinal diseases. He has a background in ophthalmology and has been involved in advancing treatments in this specialized field.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-14 | EYPT | EyePoint, Inc. | F — Tax withholding / forfeiture | 8.1K | $14.72 | $119K |
| 2026-07-14 | EYPT | EyePoint, Inc. | M — Option exercise | 16.7K | $0.00 | |
| 2026-03-24 | EYPT | EyePoint, Inc. | J — Other acquisition / disposition | 76.8K | $13.11 | $1.01M |
| 2026-03-24 | EYPT | EyePoint, Inc. | J — Other acquisition / disposition | 76.8K | $13.11 | $1.01M |
| 2026-03-16 | EYPT | EyePoint, Inc. | P — Open-market purchase | 1.5K | $13.15 | $20K |
| 2025-07-10 | EYPT | EyePoint, Inc. | F — Tax withholding / forfeiture | 7.7K | $11.06 | $85K |
| 2025-07-10 | EYPT | EyePoint, Inc. | M — Option exercise | 16.7K | $0.00 |
Jay S. Duker is the President and CEO of EyePoint Pharmaceuticals, Inc., a company focused on developing innovative therapeutics for retinal diseases. He has a background in ophthalmology and has been involved in advancing treatments in this specialized field.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($20K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Duker Jay S. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.